Clinical trial
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB…
NCT00025285 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00025285 |
|---|---|
| Title | Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, irinotecan hydrochloride, thalidomide |
| Enrollment | 46 |
| Start date | Nov 1, 2001 |
| Primary completion | Sep 29, 2004 |
| Completion | Sep 29, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 9, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: